HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kawabata, H. Articles by Uchiyama, T. Search for Related Content PubMed PubMed Citation Articles by Kawabata, H. Articles by Uchiyama, T.

Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s disease

^* Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan 606-8507
^° Proteomics Research Unit, Division of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan 920-0293;
^# Department of Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan 565-0871

Correspondence: Hiroshi Kawabata, Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan 606-8507. Fax: international +81.75.7514963. E-mail: hkawabat{at}kuhp.kyoto-u.ac.jp

We report two cases of multicentric Castleman’s disease (MCD) whose serum hepcidin levels were rapidly down-regulated by administration of tocilizumab, an anti- interleukin 6 (IL-6) receptor antibody. Our results indicate that IL-6-induced hepcidin over-production may be involved in the pathophysiology of microcytic anemia commonly observed in this disease.

Key words: interleukin-6, Castleman’s disease, tocilizumab, iron metabolism, hepcidin.